Description

The nucleic acid drugs sector consists of three major sub-sectors--aptamer therapeutics, antisense therapeutics, and RNA interference. Recent partnerships and alliances show an amalgamation of collaborations for discovery platforms and delivery technologies as well as drug entities. This report analyzes the R&D portfolio trends in these sub-sectors and then uses the Analytical Hierarchy Process (AHP) to prioritize different options that can be executed to design a strategic R&D portfolio,which showcases a company’s innovation capacity and also leads to higher credibility among investors. Portfolio options have been prioritized on a disease basis which is the one commonly followed by both big pharmaceuticals and biotech companies.